SCHEMBL22652121

SCHEMBL22652121

O=C1CCOCCN1CCCNc1cc(Cl)ncc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 1/20 0.44
ULK2 Q8IYT8 1/20 0.44
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
ITGB2 P05107 2/20 0.39
ICAM1 P05362 2/20 0.39
ITGAL P20701 2/20 0.39
KDM4E B2RXH2 3/20 0.37
FGFR1 P11362 2/20 0.36
SRC P12931 2/20 0.36
FGFR2 P21802 1/20 0.36
FGFR4 P22455 1/20 0.36
FGFR3 P22607 1/20 0.36
KMT2A Q03164 2/20 0.36
HSD17B10 Q99714 2/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22648420 0.86 ULK1 (0.52) ULK1ULK2ALDH1A1SMN1; SMN2ITGB2
SCHEMBL22648265 0.80 ULK1 (0.47) ULK1ULK2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL22648429 0.74 ULK1 (0.43) ULK1ULK2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL22672880 0.74 ULK1 (0.52) ULK1ULK2SMN1; SMN2ITGB2ICAM1
SCHEMBL22634742 0.72 SMN1; SMN2 (0.43) ULK1ULK2ALDH1A1SMN1; SMN2ITGB2
SCHEMBL25008208 0.72 ULK1 (0.58) ULK1ULK2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL22648277 0.72 TBK1 (0.45) ULK1ULK2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL25162620 0.71 ALDH1A1 (0.49) ALDH1A1ITGB2ICAM1ITGALFGFR1
SCHEMBL25918880 0.71 ALDH1A1 (0.44) ULK1ULK2ALDH1A1SMN1; SMN2ITGB2
SCHEMBL22648262 0.71 ULK1 (0.39) ULK1ULK2ALDH1A1SMN1; SMN2ITGB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3966207-B1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS LLC (US) 2023-11-01 EP disclosed
US-20230047915-A1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-02-16 US disclosed
US-11530206-B2 Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2022-12-20 US disclosed
WO-2020231806-A1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2020-11-19 WO disclosed
US-20200354352-A1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2020-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047915-A1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 ULK1 4/4885ULK2 8/4885ALDH1A1 2874/4885
US-11530206-B2 Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof BECN1, SQSTM1, ATG7 ULK1 4/4885ULK2 9/4885ALDH1A1 2271/4885
US-20200354352-A1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 ULK1 4/4885ULK2 9/4885ALDH1A1 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.